Non-alcoholic steatohepatitis (NASH) is the more aggressive form of non-alcoholic fatty liver disease (NAFLD) and is the manifestation of the metabolic syndrome. NASH is a major cause of chronic liver disease, in fact the fastest growing liver disease worldwide. However, it is often not diagnosed until at an advanced stage of the disease and there is an urgent need for a pharmacological treatment for patients with NASH. It is clear that NASH requires a holistic approach and that is why the PanNASH initiative was launched with a group of international experts. The year 2020 confirmed that Peroxisome proliferator-activated receptors (PPARs) and specifically a PanPPAR approach combining the three isoforms (PPARα, PPARδ - also called PPARβ - and PPARγ) could play an important role in the management of NASH. We hope to see more advances in the field in 2021. In addition, we are proud to announce that our group will expand in 2021 with representatives from Asia who will share their expertise in our educational project. On behalf of the editors of the PanNASH web site, we wish you a happy 2021 despite the current challenges. We will make the best possible use of this digital media to keep you informed about new data and insights on NASH and the role of PPARs.